About

Nosheen Reza, M.D., M.S., is an Assistant Professor of Medicine in Cardiovascular Medicine at the Hospital of the University of Pennsylvania and an Associate Member of the Institute for Translational Medicine and Therapeutics at the Perelman School of Medicine. She serves as the Associate Program Director for the Cardiovascular Disease Fellowship at the Perelman School of Medicine and the University of Pennsylvania Health System. Dr. Reza is also the Director of the Penn Women in Cardiology Program and a Faculty Advisor for the FOCUS on Health & Leadership for Women Section for Residents and Fellows. Her clinical expertise includes inherited cardiomyopathies such as familial cardiomyopathy, dilated cardiomyopathy, hypertrophic cardiomyopathy, arrhythmogenic cardiomyopathy, non-compaction cardiomyopathy, and restrictive cardiomyopathy. She specializes in cardiovascular genetics, advanced heart failure, mechanical circulatory support, ventricular assist devices, and cardiac transplantation. Her research focuses on inherited cardiomyopathies, cardiovascular genetics and genomics, and advanced heart failure, contributing to the understanding and management of genetic heart diseases and heart failure. Dr. Reza has authored numerous publications on these topics and is actively involved in advancing the field through her clinical and translational research.

Research topics

• Medicine
• Internal medicine
• Cardiology
• Intensive care medicine
• Family medicine

Selected publications

• Characteristics And Outcomes Of Patients With Hypertrophic Cardiomyopathy Stratified By Referral Source

  Journal of Cardiac Failure · 2026-01-01

  articleSenior author
  PublisherDOI

• Can Artificial Intelligence Replace our Journal’s Editorial Board?

  Journal of Cardiac Failure - Intersections · 2026-03-01

  articleOpen accessSenior author

  Welcome to the fourth issue of the Journal of Cardiac Failure-Intersections. We are once again thrilled to bring you innovative research, impassioned debates, and provocative perspectives from authors and investigators who have been unafraid to explore and exploit the unique collaborations and imaginative discoveries that happen only at cardiovascular medicine’s many intersections. As a maturing editorial team, we finally feel like we are hitting our stride. The anxiety of cultivating a new journal and bringing content to a hungry readership has now been firmly replaced by an increasingly confident, perhaps even bold attitude.

  PublisherOA PDFDOI

• Setting Yourself up for Success as an Early Career Investigator in Clinical Trials

  JACC Advances · 2026-04-25

  articleOpen access
  PublisherDOI

• Quantifying The Diagnostic Trajectory In Patients With Hypertrophic Cardiomyopathy

  Journal of Cardiac Failure · 2026-01-01

  articleSenior author
  PublisherDOI

• Concomitant GLP-1 Receptor Agonist Therapy Is Associated With Significant Weight Reduction In Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten

  Journal of Cardiac Failure · 2026-01-01

  article
  PublisherDOI

• Criteria to Assess the Predictive and Clinical Utility of Novel Models, Biomarkers, and Tools for Risk of Cardiovascular Disease: A Scientific Statement From the American Heart Association

  Circulation · 2026-02-11 · 4 citations

  articleOpen access

  Risk prediction has been used in the primary prevention of cardiovascular disease for >3 decades. Contemporary cardiovascular risk assessment relies on multivariable models, which integrate established cardiovascular risk factors and have evolved over time from the Framingham Risk Model to the pooled cohort equations to the PREVENT (Predicting Risk of CVD Events) equations. Recent scientific (ie, genomics, proteomics, metabolomics) and methodologic (ie, artificial intelligence) advances have led to a proliferation of novel models, biomarkers, and tools for potential use in risk prediction. In parallel, the growing armamentarium of preventive therapies, some with considerable cost, underscores the need for more accurate and precise risk assessment to prioritize those at highest risk who will derive the greatest absolute benefit. Accompanying the considerable enthusiasm for the potential of newer approaches to improve risk prediction is the need for rigorous evaluation and assessment of their performance (ie, accuracy, precision, incremental performance when added to contemporary multivariable risk models or established risk factors) and clinical utility (ie, actionability, scalability, generalizability) before adoption in clinical practice. Additional considerations in risk tool evaluation include reproducibility, cost-value considerations (including impact on downstream health care costs), and implications for health equity. This scientific statement defines a standardized framework for general considerations in risk prediction, statistical assessment of predictive utility, and critical appraisal of clinical utility and readiness. This scientific statement is intended to support clinicians, researchers, and policymakers in how best to evaluate current and emerging risk prediction tools and ultimately improve the prevention of cardiovascular disease in diverse populations.

  PublisherOA PDFDOI

• Antihypertensive Dosing During Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy

  Journal of Cardiac Failure - Intersections · 2026-01-02

  articleOpen access1st authorCorresponding
  PublisherOA PDFDOI

• <i>RBM20</i> Truncating Variants and Human Cardiomyopathy

  JAMA Cardiology · 2026-04-08

  articleOpen access

  Importance: Genetic diagnosis has become increasingly important to guide clinical decision-making for patients with dilated cardiomyopathy (DCM). Pathogenic or likely pathogenic (P/LP) missense variants in the gene RBM20 cause a highly penetrant arrhythmogenic DCM, but the role of RBM20 truncating variants (RBM20tvs) is unclear. Objective: To assess the contribution of RBM20 variants to arrhythmogenic DCM. Design, Setting, and Participants: In this cohort study, participants in the genome-first UK Biobank (UKB) and All of Us populations were evaluated to assess the etiologic fraction, natural history and penetrance of RBM20 variants. Retrospective data were collected from an international cohort of patients with DCM and RBM20 variants identified at centers of excellence for genetic heart disease and compared based on time to event. Study dates are not disclosed because the institutional review board did not authorize the sharing of this information. Exposures: RBM20 variants were compared to known P/LP variants and variants of uncertain significance in RBM20 as well as titin truncating variants (TTNtvs). Main Outcomes and Measures: Major ventricular arrhythmias, end-stage heart failure, and heart failure hospitalization as measured by medical record review (retrospective cohort) and diagnostic codes (UKB). Results: Two main cohorts were studied for this project. In UK Biobank, a cohort of participants with RBM20tvs, RBM20 synonymous variants, and TTNtvs was studied. Of these 4249 participants, 1869 (44%) were male. The mean (SD) age at enrollment was 56 (8.2) years. In the RBM20 registry, of 179 patients, 105 (58.6%) were male, and the mean (SD) age at enrollment was 43.8 (19.1) years. A validation cohort from the All of Us biobank was also used. This consisted of 7002 participants, 4342 of whom (62.0%) were male, and the mean (SD) age was 52.7 (16.7) years. The etiologic fraction of RBM20 variants in arrhythmogenic DCM was 0.53 (95% CI, 0.32-0.67; P < .001). In genome-first biobanks, lifetime incidence of cardiomyopathy, heart failure, or major ventricular arrhythmia diagnosis was lower in participants with RBM20 variants than in those with TTNtvs (hazard ratio, 0.55; 95% CI, 0.36-0.84; P < .001). Patients with RBM20tvs and DCM presented to referral centers later in life than those with P/LP RBM20 and DCM (mean [SD], 53 [10] vs 34 [18] years; P < .001) and were less likely to have a family history of sudden cardiac arrest (2 of 10 [20%] vs 11 of 17 [65%]; P = .046) or cardiomyopathy (2 of 10 [20%] vs 14 of 18 [78%]; P < .001). There was no significant difference in age- and sex-adjusted incident major heart failure or arrhythmia events between patients with RBM20tv and DCM or those with P/LP RBM20 and DCM, though sex-adjusted lifetime hazard was reduced in those with RBM20tv and DCM (hazard ratio, 0.13; 95% CI, 0.03-0.56; P = .01). Conclusions and Relevance: This study found that RBM20 variants contributed to arrhythmogenic DCM phenotypes but conferred reduced lifetime disease penetrance compared to TTNtvs and milder disease severity alone than P/LP RBM20 variants. Their potential for additive interactions with other damaging variants should be considered in patients with DCM and their families.

  PublisherOA PDFDOI

• Therapeutic Sequencing in Obstructive Hypertrophic Cardiomyopathy

  JACC Heart Failure · 2025-12-09

  articleOpen access1st authorCorresponding
  PublisherOA PDFDOI

• Innovation Without Boundaries – The Genesis of Journal of Cardiac Failure-Intersections

  Journal of Cardiac Failure - Intersections · 2025-09-01

  articleOpen accessSenior author
  PublisherOA PDFDOI

Recent grants

• Improving the Detection of Hypertrophic Cardiomyopathy Using Machine Learning Applied to Electronic Health Record Data

  NIH · $519k · 2023–2028

Frequent coauthors

• Anjali Owens

  University of Pennsylvania

  68 shared

• Edo Y. Birati

  Bar-Ilan University

  27 shared

• Jonathan B. Edelson

  Children's Hospital of Philadelphia

  24 shared

• Kimberly Y. Lin

  Children's Hospital of Philadelphia

  23 shared

• Jonathan J. Edwards

  University of Pennsylvania

  21 shared

• Joseph W. Rossano

  Children's Hospital of Philadelphia

  19 shared

• Hannah Katcoff

  University of Pennsylvania

  17 shared

• Danielle S. Burstein

  University of Vermont

  16 shared